baber/WOPTO huggingface dataset:
Patent NZ-332858-A (NZ)
Title: Malted beverage powder and process comprising heating malted ingredients with less than 9 percent moisture by weight, cooling the extruded molten mass then grinding into a powder
Inventor: GEROMINI OSVALDO
IPC: A23L7/20
Filed: 1998-11-18
Abstract: A process for the production of a malted beverage powder and the beverage powder so produced. Malted beverages are well known and are primarily intended as nutritive drinks. The process provides a method that is capable of producing a malted beverage powder that retains flavour and texture comparable to those produced by conventional vacuum drying processes. The malted beverage ingredients preferably contain from 15% to 50% by weight malt. The malt may be in the form of a liquid malt extract or a malt powder, or both. The malted beverage ingredients further comprise of 15% to 30% by weight of a powdered or granulated sweetener. The process comprises: 1. Introducing malted beverage ingredients into an extruder, the malted beverage ingredients having a total moisture content of less than 9% by weight; 2. Heating the malted beverage ingredients in the extruder to a temperature sufficient to provide a molten mass but less than 150oC; 3. Extruding the molten mass through one or more orifices to provide an expanded extrudate; 4. Cooling the expanded extrudate to stabilise the expanded structure of the expanded extrudate; and 5. Comminuting the expanded extrudate to powder. The process also provides substantial advantage that little or no drying of the product is required, greatly reducing energy consumption.
Patent NZ-502162-A (NZ)
Title: Method for producing bags comprising closure profiles actuated by a slider
Inventor: BOIS HENRI GEORGES
IPC: B31B19/90
Filed: 1999-05-04
Abstract: A method of automatically manufacturing bags fitted with complementary closure strips (30, 40) comprises the steps consisting in: supplying at least one moving film (110) adapted to form bag walls; supplying at least one moving closure assembly (10) comprising a W-shaped support sheet (20) constituting both an internal channel-section tamperproofing tape (22) provided on its facing internal surfaces (23, 24) with respective complementary closure strips (30, 40), and also external lateral webs (26, 28) extending beyond the closure strips (30, 40) and the internal channel-section tape (22).  The closure assembly (10) also are prefitted with a series of sliders (50) for actuating the closure strips (30, 40) and are distributed along the length of the closure assembly (30, 40) as fed; and fixing the closure assembly (10) formed in this way, via the external lateral support webs (26, 28) to the film (110) forming the bag wall. A machine for automatically manufacturing bags fitted with complementary closure strips (30, 40) for implementing the method. The machine comprises means (112) suitable for supplying at least one moving film (110) suitable for forming bag walls and means suitable for supplying a moving closure assembly (10) comprising a W-shaped support sheet (20) constituting both an internal channel-section tamperproofing tape (22) provided on its facing internal surfaces (23, 24) with respective complementary closure strips (30, 40), and also external lateral webs (26, 28) which extend beyond the closure strips (30, 40) and the internal channel-section tape (22).  The closure (10) is also prefitted with a series of sliders (50) for actuating the closure strips (30, 40).  Sliders (50) are distributed along the length of the closure strip as delivered.  Means (130) is suitable for fixing the resulting closure assembly (10) via its external lateral support webs (30, 40) to the film (110) forming the bag wall.
Patent NZ-514330-A (NZ)
Title: Zinc containing dentifrice compositions
Inventor: YU DAHSHEN
IPC: A61K8/24
Filed: 2000-02-16
Abstract: A dentifrice composition comprises zinc citrate, a buffer system, an abrasive; and an oral vehicle. The dentifrice composition has a pH from 3.0 to 5.5. The zinc citrate is in an amount sufficient to provide at least 2000 ppm of zinc ion and the amount of zinc ion that is bioavailable is at least 1000 ppm.
Patent NZ-514431-A (NZ)
Title: Stand-up bag
Inventor: SCHULZ WERNER
IPC: B65D75/00
Filed: 2000-03-29
Abstract: An easy-to-open stand-up bag of a heat-sealable plastic film has two opposing side walls (1, 2) with side seams (5, 6) along their lateral edges, an inwardly folded bottom wall (4) and an inwardly folded top wall (3). One of the side walls (1) comprises a first side wall section (1a) and a second side wall section (1b) which overlaps the first side wall section (1a) in an overlapping area (15) having longitudinal peelable connections (19, 20) along the side seams (5, 6) and a transverse peelable connection (18). The second side wall section (1b) extends past the transverse peelable connection (18) to form a gripping member.
Patent NZ-515655-A (NZ)
Title: Control of wool growth in sheep and related animals
Inventor: BROWNLEE ALAN GEORGE
IPC: A61D7/00
Filed: 2000-05-19
Abstract: A method for the control ablation of wool follicles within skin of a wool bearing animal, for use in methods such as non-surgical mulesing, non-surgical pizzle-ringing and crutching of sheep, the method comprising: treating the skin at one or more selected localities with a composition comprising at least one follicle-ablating agent and, subsequently irradiating the skin at the selected localities with electromagnetic radiation of an intensity and/or wavelength to bring about the photodynamic ablation of at least a portion of the wool follicles in the skin at the selected localities.
Patent NZ-516029-A (NZ)
Title: Preparation and use of gamma-butyrolactones as cross- linking agents
Inventor: ANDERSON ALBERT GORDON
IPC: C08F8/30
Filed: 2000-06-13
Abstract: A lactone composition has the formula (I) and is used as a cross linking agent in a coating composition containing amine compound(s) that are reactive with lactone groups is disclosed wherein: each n is independently 1 to 3; L is either a substituent having two functional groups, a direct bond forming a spiro-bislactone or H wherein rings of the formula (I) are not connected; Y is alkenyl, alkynyl, or aryl or is a direct bond; each X is independently a substituent selected from the group consisting of and identified with the numbers 1 to 530 as defined in Table 1 of the specification; provided that when L is a substituent having two functional groups, L is not represented by formula (a) or formula (b).
Patent NZ-517445-A (NZ)
Title: Rhodamine diagnostic agent and diagnostic methods for detection of epithelial cancer
Inventor: BURKETT DOUGLAS D
IPC: A61K/
Filed: 2000-06-30
Abstract: A diagnostic method for identifying and delineating cancerous epithelial tissue comprising: a) applying rhodamine to the epithelium, to selectively mark cancerous tissue; and b) visually examining said epithelium, to identify and delineate suspected cancerous tissue sites, by comparing the colour of the suspected sites with the colour of the adjacent tissue; wherein the method does not include a surgical step. Also disclosed is a dye composition containing rhodamine which is selectively retained by cancerous and precancerous tissue.
Patent NZ-518798-A (NZ)
Title: Preparation of particulate compositions by wet milling a sparingly water-soluble drug substance as an aqueous dispersion in a multi-chamber bead mill, where the aqueous dispersion also comprises a soluble carrier, a surfactant and an anti-agglomeration agent
Inventor: DUMPLETON DAVID ROBERT
IPC: A61K9/14
Filed: 1998-12-14
Abstract: A process for preparing a particulate composition of a sparingly water-soluble drug substance which comprises: wet milling the drug substance as an aqueous dispersion in a multi-chamber bead mill with circulation of product between the chambers. The aqueous dispersion including a soluble carrier suitable as an excipient for spray drying. A surfactant to maintain the particles in suspension on resuspension. And an anti-agglomeration agent effective after administration of a pharmaceutical formulation to a patient, and spray drying the aqueous dispersion after milling. The drug substance may include a compound of formula I or II.
Patent NZ-519752-A (NZ)
Title: Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
Inventor: COOLIDGE THOMAS R
IPC: A61K38/26
Filed: 2001-10-22
Abstract: Disclosed is the use of a compound comprising GLP-1 or a biologically active variant analogue, or derivative thereof, in the manufacture of a medicament for the treatment of an individual with hibernating myocardium. Also disclosed is the use of a compound comprising exendin or a biologically active variant, analogue or derivative thereof, in the manufacture of a medicament for the treatment of an individual to decrease plasma or cardiac levels of norepinephrine.
Patent NZ-521155-A (NZ)
Title: Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication
Inventor: THEOBALD FRANK
IPC: A61P25/34
Filed: 2001-04-02
Abstract: A transdermal or transmucosal pharmaceutical form for the treatment of nicotine dependency or disaccustoming smokers which comprises nicotine, a nicotine salt, a nicotine derivative or a nicotinergic substance in combination with at least one further active substance comprises at least one substance which acts on the central nervous system and is selected from the group of psychopharmaceuticals which embraces the active-substance groups of the antidepressants, transquilizers, nootropics, neuoleptics, or psychomimetics.
Patent NZ-521730-A (NZ)
Title: Industrial textiles assembled from pre-crimped components
Inventor: HARRISON JAMES
IPC: D03D15/02
Filed: 2001-04-03
Abstract: A industrial textile (10) comprising interconnected longitudinal and horizontal components, wherein at least a portion of the longitudinal and/or horizontal components are formed of a polymeric material, characterised in that the longitudinal components (20) are pre-crimped so as to provide a plurality of bottom side indentations (22) and top side indentations (24) extending over an entire length thereof. The indentations formed by the pre-crimping are substantially complementary to a cross-sectional size of the horizontal components thereby allowing the horizontal components to be received and secured into position in the assembled fabric without further substantial deformation of the longitudinal components.
Patent NZ-525771-A (NZ)
Title: Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
Inventor: HADLEY MICHAEL STEWART
IPC: C07D495/04
Filed: 2001-11-12
Abstract: Tetrahydrobenzazepine derivative compounds of formula (I) are disclosed, wherein R1 to R4, A, B and t are as defined in the specification. These compounds are modulators of dopamine D3 receptors and have potential in the treatment of psychotic conditions (e.g. schizophrenia) or substance abuse.
Patent NZ-526867-A (NZ)
Title: Novel multi-ring organic compounds for regulating gut motility and food intake
Inventor: KRANTIS ANTHONY
IPC: A61K31/352
Filed: 2002-01-11
Abstract: Multi-ring organic compounds (see compound I below) are described. These compositions are useful in methods for regulating gut motility to modulate food intake and treat obesity and malnutrition
Patent NZ-529330-A (NZ)
Title: Tomato plants that exhibit resistance to Botrytis cinerea
Inventor: GABOR BRAD KANE
IPC: A01H5/08
Filed: 2002-04-24
Abstract: Disclosed is a Botrytis resistant Lycopersicon esculentum plant having a genome that comprises at least one region on chromosome 10 which contains at least one gene that encodes for Botrytis resistance. The region on chromosome 10 has been introgressed into the genome of the plant from another Lycopersicon plant and furthermore the region comprises at least one molecular marker selected from TG313, CT234, TG408, CT20, CT57, TG241, TG233 and CD32B.
Patent NZ-530511-A (NZ)
Title: A tablet for treating disorders of the gastrointestinal tract comprising a proton pump inhibitor and at least one antacid that has a barrier layer to cover an enteric coating film
Inventor: CRIERE BRUNO
IPC: A61K45/06
Filed: 2002-07-10
Abstract: Described is a multiparticulate tablet that disintegrates in the mouth containing: i) a proton pump inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO3 and/or Mg(OH)2 and/or Al(OH)3; and, iii) a mixture of excipients comprising at least one disintegrating agent, one diluent agent, a lubricant, and optionally a swelling agent, a permeabilising agent, sweeteners, flavourings and colours. Furthermore, described is the processes for the manufacture of the tablet and its use in the treatment of gastrointestinal disorders.
Patent NZ-531193-A (NZ)
Title: Compounds effecting glucokinase
Inventor: CAULKETT PETER WILLIAM RODNEY
IPC: A61K31/426
Filed: 2002-08-15
Abstract: A compound of Formula (Ib) is disclosed. Also disclosed is, a pharmaceutical composition comprising a compound according to this formula and a process for the preparation of a compound of formula (Ib). The compounds described are useful in the preparation of a medicament for use in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK), such as type 2 diabetes.
Patent NZ-533521-A (NZ)
Title: New crystalline forms of meloxicam and processes for their preparation and interconversion
Inventor: COPPI LAURA
IPC: C07D417/02
Filed: 2002-11-19
Abstract: Disclosed is a method for preparing the crystalline form I of meloxicam, represented by the formula (I): that involves dissolving meloxicam in a mixture consisting of water and NaOH, and subsequent addition of an acid for precipitation of the crystalline form I of meloxicam, maintaining throughout the process a temperature between 65°C and the reflux temperature. Further disclosed is a method for preparing the crystalline form I of meloxicam, wherein the meloxicam is dissolved in a mixture consisting of water, NaOH and an organic solvent selected from: an alcohol, xylene, toluene and dimethylformamide, and wherein the temperature maintained throughout the process is between 50°C to the reflux temperature.
Patent NZ-534069-A (NZ)
Title: 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
Inventor: BARVIAN MARK ROBERT
IPC: C07D471/04
Filed: 2003-01-10
Abstract: Substituted 2-aminopyridines of formula (I) are disclosed, wherein the variables are as defined in the specification. These compounds are potent inhibitors of cyclin-dependent kinases 4 (Cdk4) and are useful in treating disorders or conditions caused by abnormal cell proliferation, wherein the abnormal cell proliferation is a cancer selected from the group consisting of cancers of the breast, ovary, cervix, prostate, testis, esophagus, stomach, skin, lung, bone, colon, pancreas, thyroid, biliary passages, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, glioblastoma, neuroblastoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, adenocarcinoma, adenoma, adenocarcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, and leukemia.
Patent NZ-534211-A (NZ)
Title: Lyophilized preparation containing antibodies to the EGF receptor
Inventor: MAHLER HANNS-CHRISTIAN
IPC: A61K47/34
Filed: 2002-11-25
Abstract: Described is a lyophilised, pharmaceutical preparation containing an antibody to the receptor of the endothelial growth factor (EGF receptor). The preparation has storage stability, even at high temperatures and once reconstituted, can be used parenterally for the treatment of tumours.
Patent NZ-535613-A (NZ)
Title: Indolylmaleimide derivatives useful to treat diseases mediated by T lymphocytes and/or PKC, or T-cell mediated acute inflammatory diseases
Inventor: EVENOU JEAN-PIERRE
IPC: C07D401/14
Filed: 2003-04-02
Abstract: Disclosed are compounds of formula (I), which are useful in the treatment and/or prevention of diseases or disorders mediated by T lymphocytes and/or PKC, e.g. acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycystic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury e.g. myocardial infraction, stroke, gut ischemia, renal failure or haemorrhage shock, or traumatic shock, e.g. traumatic brain injury. The compounds of formula (I) are also useful in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders or autoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, Hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, e.g. angiopathy, diabetic proliferative retinopathy, diabetic macular edema, nephropathy, neuropathy and dawn phenomenon, respiratory diseases such as asthma or inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, cutaneous manifestations of immunologically-mediated disorders or illnesses, inflammatory and hyperproliferative skin diseases (such as psoriasis, atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome, keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn's disease or ulcerative colitis.
Patent NZ-538083-A (NZ)
Title: Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
Inventor: BACHMANN MARTIN F
IPC: A61K39/35
Filed: 2003-07-14
Abstract: A composition comprises an AP205 virus like particle (VLP) and an antigen. Also disclosed is a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP is useful for producing a composition for inducing an immune response for the prevention or treatment for diseases, disorders or condition such as infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses.
Patent NZ-540365-A (NZ)
Title: Crystalline derivative of 2-(5-chlorothien-2-yl)-N-((3S)-1((1S)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl)ethensulfonamide
Inventor: DELL ORCO PHILIP C
IPC: C07D409/12
Filed: 2003-12-04
Abstract: Disclosed is (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees and wherein substantially crystalline means containing less than 50% of the amorphous form (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide. Also disclosed is a method for the preparation of crystalline (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide comprising crystallisation of (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide from an organic solution, optionally in the presence of water.
Patent NZ-540668-A (NZ)
Title: Hay rake with steering rear wheels
Inventor: GIOVANNINI ADELMO
IPC: A01B69/08
Filed: 2005-06-13
Abstract: Hay rake towed by tractor or similar, able to perform changes of direction with a very narrow turning radius, carried out by use of steering rear wheels. In particular the rear wheels steer in the opposite direction to those of the tractor and steering is controlled by mechanisms that can be activated actively and/or passively by the towing tractor.
Patent NZ-549225-A (NZ)
Title: Detection and typing of Lactobacillus bacterial strains, and isolated nucleotides from such
Inventor: RUSSELL W MICHAEL
IPC: C12Q1/68
Filed: 2005-04-28
Abstract: Disclosed are isolated polynucleotide sequences from several Lactobacillus species, including L. acidophilus, L. brevis, L. casei, and L. delbrueckii. All sequences relate to CRISPR loci, which are repetitive regions that are highly conserved within species, but show low similarity between species. In particular the CRISPR region of L. acidophilus is disclosed. Further disclosed are methods and kits for the detection and typing of Lactobacillus bacterial strains from in vitro samples, food products, dietary supplements, and environmental samples, primarily using the CRISPR sequence of L. acidophilus as a reference.
Patent NZ-549550-A (NZ)
Title: Composition containing thiamethoxam, clothianidin or dinotefuran that prevents damage to trees by harmful insects and a prevention method thereof
Inventor: WATANABE KUNITOSHI
IPC: A01N25/00
Filed: 2005-03-10
Abstract: Disclosed is a method for controlling damage to trees caused by harmful insects, said method comprising injecting said trees with a formulation comprising: thiamethoxam, a water miscible solvent selected from lower alcohols and ketones, and a non-ionic surfactant. Reference has been directed, in pursuance of Section 16 of the Patents Act, 1953, to New Zealand patent 549549.
Patent NZ-554898-A (NZ)
Title: Building with a safety line attached and supported by guttering to prevent a person from falling
Inventor: HEAVEN DARRYLL LAWRENCE
Filed: 2007-05-02
Abstract: This discloses a building 2 fitted with a safety line, the safety line running along and within the guttering 3, 5 which form part of the building and secured to the building 2 directly or indirectly at intervals 8. The safety line is arranged so that it can withstand the full body weight of an average sized adult 11in case the adult 11 were to fall from the roof.
Patent NZ-555296-A (NZ)
Title: Twin wire gap former paper making machine with variable wrap impingement shoe
Inventor: HELBIG THOMAS
IPC: D21F1/24
Filed: 2005-11-16
Abstract: A forming section for a gap blade former type papermaking machine having a headbox which delivers a jet of papermaking stock between a conveying forming fabric and a backing forming fabric is provided. The conveying fabric moves in sliding contact over an impingement shoe on which the jet of papermaking stock is delivered at a point of impingement. A forming shoe located immediately downstream of the impingement shoe over which the backing forming fabric slides. The impingement shoe is mounted for at least one of pivoting and transverse movement so that a position of the point of impingement of the jet of papermaking stock can be adjusted by at least one of rotating the impingement shoe about a first pivot point and transversely shifting the impingement shoe. The forming shoe can also be mounted for movement.
Patent NZ-560800-A (NZ)
Title: Modification of plant and seed development and plant responses to stresses and stimuli (3)
Inventor: SPANGENBERG GERMAN
IPC: C12N15/29
Filed: 2002-05-07
Abstract: Provided is a substantially purified or isolated nucleic acid or nucleic acid fragment encoding a late embryogenesis abundant protein (LEA) from a Lolium species. Further provided are corresponding peptides, vectors containing the nucleic acid sequences, plants containing the nucleic acid sequences and methods of modifying plant responses to stress or seed development and germination using the said vectors.